PDF(Pubmed)
Abstract：
UNASSIGNED: Radiotherapy (RT) is an appropriate treatment option for early-stage glottic cancer (ESGC) that achieves high local control and preserves voice quality. However, the optimal radiation treatment schedule remains unknown. We present our institution\'s 14-year experience in treating ESGC with definitive radiotherapy between 2005 and 2019 inclusively.
UNASSIGNED: We reviewed the medical records of 104 patients; 63 (60.5%) were treated with conventional fractionation (CF), and 41 (39.5%) were treated with hypofractionated radiotherapy (HF). The clinical T-stage was T1a in 50 patients (48%), T1b in 27 (26%), and T2 in 27 (26%). Age, gender, anterior commissure involvement, stage, radiotherapy technique, radiation fraction size, and overall treatment time (OTT) were analyzed as prognostic factors. The survival outcomes, local regional control (LRC), and laryngeal preservation rate were evaluated.
UNASSIGNED: The 5-year overall survival (OS) and LCR were 83.3% and 78%, respectively. On univariate analysis, treatment with CF (p = 0.02), prolonged OTT > 49 days in CF and > 40 days in HF (p = 0.04), and RT total dose < 66 Gy (p = 0.03) were associated with poor LRC. Multivariate analysis showed a non-significant association with LRC (all p > 0.05). The 5-year OS rate in the CF and HF-treated patients was 84.9% and 72.1%, respectively (p = 0.99), and in patients who had T1a, T1b, and T2 disease, were 78.2%, 96.0%, and 82.1%, respectively (p = 0.43). All patients and tumor variables showed no statistically significant association with OS. Only low-grade acute toxicity was observed.
UNASSIGNED: Non-inferiority results supported the HF schedule to ESGC, including high local disease control and decreased overall treatment time. Our study supports its efficacy in the primary care of ESGC with manageable side effects.
UNASSIGNED: We reviewed the medical records of 104 patients; 63 (60.5%) were treated with conventional fractionation (CF), and 41 (39.5%) were treated with hypofractionated radiotherapy (HF). The clinical T-stage was T1a in 50 patients (48%), T1b in 27 (26%), and T2 in 27 (26%). Age, gender, anterior commissure involvement, stage, radiotherapy technique, radiation fraction size, and overall treatment time (OTT) were analyzed as prognostic factors. The survival outcomes, local regional control (LRC), and laryngeal preservation rate were evaluated.
UNASSIGNED: The 5-year overall survival (OS) and LCR were 83.3% and 78%, respectively. On univariate analysis, treatment with CF (p = 0.02), prolonged OTT > 49 days in CF and > 40 days in HF (p = 0.04), and RT total dose < 66 Gy (p = 0.03) were associated with poor LRC. Multivariate analysis showed a non-significant association with LRC (all p > 0.05). The 5-year OS rate in the CF and HF-treated patients was 84.9% and 72.1%, respectively (p = 0.99), and in patients who had T1a, T1b, and T2 disease, were 78.2%, 96.0%, and 82.1%, respectively (p = 0.43). All patients and tumor variables showed no statistically significant association with OS. Only low-grade acute toxicity was observed.
UNASSIGNED: Non-inferiority results supported the HF schedule to ESGC, including high local disease control and decreased overall treatment time. Our study supports its efficacy in the primary care of ESGC with manageable side effects.
摘要：
■放射治疗（RT）是早期声门癌（ESGC）的适当治疗选择，可实现高局部控制并保留语音质量。然而,最佳放射治疗方案仍然未知.我们介绍了我们机构在2005年至2019年期间采用确定性放疗治疗ESGC的14年经验。
■我们回顾了104例患者的医疗记录；63例（60.5%）采用常规分割（CF）治疗，41例（39.5％）接受了大分割放疗（HF）。50例（48%）患者的临床T分期为T1a，T1b在27（26%），和T2在27（26％）。年龄,性别,前连合受累,舞台,放射治疗技术，辐射分数大小，分析总治疗时间（OTT）作为预后因素。生存结果，本地区域控制(LRC)，并评价喉保存率。
■5年总生存率（OS）和LCR分别为83.3%和78%，分别。在单变量分析中，用CF治疗（p=0.02），在CF中延长OTT>49天，在HF中延长OTT>40天（p=0.04），RT总剂量<66Gy（p=0.03）与LRC差相关。多因素分析显示与LRC无显著相关性(均p>0.05)。CF和HF治疗患者的5年OS率分别为84.9%和72.1%，分别(p=0.99)，在患有T1a的患者中，T1b,和T2疾病，是78.2%，96.0%,82.1%，分别(p=0.43)。所有患者和肿瘤变量均与OS无统计学意义。仅观察到低度急性毒性。
■非劣效性结果支持ESGC的HF时间表，包括局部疾病控制高和总体治疗时间缩短。我们的研究支持其在ESGC初级保健中的疗效，副作用可控。
■我们回顾了104例患者的医疗记录；63例（60.5%）采用常规分割（CF）治疗，41例（39.5％）接受了大分割放疗（HF）。50例（48%）患者的临床T分期为T1a，T1b在27（26%），和T2在27（26％）。年龄,性别,前连合受累,舞台,放射治疗技术，辐射分数大小，分析总治疗时间（OTT）作为预后因素。生存结果，本地区域控制(LRC)，并评价喉保存率。
■5年总生存率（OS）和LCR分别为83.3%和78%，分别。在单变量分析中，用CF治疗（p=0.02），在CF中延长OTT>49天，在HF中延长OTT>40天（p=0.04），RT总剂量<66Gy（p=0.03）与LRC差相关。多因素分析显示与LRC无显著相关性(均p>0.05)。CF和HF治疗患者的5年OS率分别为84.9%和72.1%，分别(p=0.99)，在患有T1a的患者中，T1b,和T2疾病，是78.2%，96.0%,82.1%，分别(p=0.43)。所有患者和肿瘤变量均与OS无统计学意义。仅观察到低度急性毒性。
■非劣效性结果支持ESGC的HF时间表，包括局部疾病控制高和总体治疗时间缩短。我们的研究支持其在ESGC初级保健中的疗效，副作用可控。
